Fig. 1.
Fig. 1. Adjusted Kaplan-Meier estimates of progression-free survival after rituximab treatment byFCGR3A-158V/F genotype (P = .2).

Adjusted Kaplan-Meier estimates of progression-free survival after rituximab treatment byFCGR3A-158V/F genotype (P = .2).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal